PwC MoneyTree is the go-to source for Venture Capital firms and high-growth startups.
US VC deals fall for the third consecutive quarter in Q1’20: 9% QoQ and 16% YoY. In March 2020, US deals decrease 22% YoY, with some of the decline attributable to the COVID-19 pandemic. Nonetheless, funding still rises 14% QoQ on the back of larger deals.
Nearly half of all US funding in Q1’20 comes from mega-rounds: Despite a slowdown in deals at the end of the quarter, 58 US companies raise rounds worth $100M or more in Q1’20, close to the record of 67 in Q2’19. 21 of these rounds took place in March 2020, suggesting COVID-19’s impact may become more apparent in Q2’20.
The number of unicorn companies reaches a new high, but aggregate valuation is falling. The number of VC-backed startups valued at $1B+ continues to rise, hitting 204 private companies in Q1’20. However, aggregate valuation dips for the second consecutive quarter, to $624B.
Global deal activity and funding see YoY declines. North America, Asia, and Europe see combined funding of $50B in Q1’20: falling 10% in Q1’20 compared to Q1’19. Asia sees the largest drop in funding, deal activity, declining 20% YoY, compared to declines of 17% in North America and 10% in Europe. Some of the decline is likely attributable to their earlier outbreak of the pandemic.
The PwC MoneyTree website is home to the PwC/CB Insights quarterly MoneyTree Report. It contains historical trend data (beginning in 1995), updates on the Venture Capital and high-growth startups ecosystem and relevant insights from PwC’s emerging company services and venture capital tax, audit and advisory professionals. The PwC/CB Insights MoneyTree Report is the definitive source of information on venture capital investments in emerging companies. This study is a staple of the financial community, entrepreneurs, government policymakers and the business press worldwide.
Partner, US Pharmaceuticals and Life Sciences, PwC US
US Asset and Wealth Management Leader, PwC US
Assurance Director, PwC US